title: Adoptive immunotherapy with bispecific antibodies: targeting through macrophages.
abstract: We report on two applications of bispecific antibodies to enhance the antitumoral function of human macrophages: (1) use of rhuIFN gamma (recombinant human IFN gamma) encapsulated in human red blood cells coated with anti-Fc gamma RI/anti-RhD+ bispecific antibodies to target and to activate human macrophages; encapsulated rhuIFN gamma was more potent than free IFN gamma in activating mature macrophages in vitro, demonstrating the efficacy of this delivery system to initiate in situ activation of macrophages and also to maintain a high antitumoral efficacy of macrophages with less side effects than after systemic injection of IFN gamma; (2) targeting of activated macrophages to tumours by bispecific antibodies directed against macrophage Fc gamma RI and against human adenocarcinoma antigen; differentiated human macrophages became cytotoxic for human adenocarcinoma in vitro and in vivo (tumours implanted in nude mice) when activated by rhuIFN gamma; this effect was increased in the presence of bispecific antibodies. These two approaches were aimed at increasing the efficacy of cellular immunotherapies using activated macrophages as effector cells (macrophage-activated killer, or MAK), an adoptive therapy which we have developed. Bispecific antibodies could increase specific homing and activation of cytotoxic MAK effectors at tumour sites.
authors.affiliation: Centre National de Transfusion Sanguine, Les Ulis, France.
authors.forename: M
authors.initials: M
authors.lastname: Chokri
authors.forename: A
authors.initials: A
authors.lastname: Girard
authors.forename: M C
authors.initials: MC
authors.lastname: Borrelly
authors.forename: C
authors.initials: C
authors.lastname: Oleron
authors.forename: J L
authors.initials: JL
authors.lastname: Romet-Lemonne
authors.forename: J
authors.initials: J
authors.lastname: Bartholeyns
mesh_terms: D000906:Antibodies / Q000008:administration & dosage*; D000943:Antigens, Differentiation; D003432:Cross-Linking Reagents; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000008:administration & dosage; D007518:Isoantibodies / Q000008:administration & dosage; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology*; D014677:Pharmaceutical Vehicles; D011961:Receptors, Fc; D017452:Receptors, IgG; D011994:Recombinant Proteins; D012204:Rh-Hr Blood-Group System
chemical_list: D000906:Antibodies; D000943:Antigens, Differentiation; D003432:Cross-Linking Reagents; D007518:Isoantibodies; D014677:Pharmaceutical Vehicles; C033242:RH-antibodies; D011961:Receptors, Fc; D017452:Receptors, IgG; D011994:Recombinant Proteins; D012204:Rh-Hr Blood-Group System; D007371:Interferon-gamma